Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.

Xia, Feng; Wu, Li-Li; Lau, Wan-Yee; Huan, Hong-Bo; Wen, Xu-Dong; Ma, Kuan-Sheng; Li, Xiao-Wu; Bie, Ping

Xia, Feng; Wu, Li-Li; Lau, Wan-Yee; Huan, Hong-Bo; Wen, Xu-Dong; Ma, Kuan-Sheng; Li, Xiao-Wu; Bie, Ping.

Afiliação

Xia F; Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
Wu LL; Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
Lau WY; Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
Huan HB; Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
Wen XD; Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
Ma KS; Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
Li XW; Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.
Bie P; Feng Xia, Li-Li Wu, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, China.

World J Gastroenterol ; 22(23): 5384-92, 2016 Jun 21.

Article em En | MEDLINE | ID: mdl-27340354

Assuntos

Carcinoma Hepatocelular/terapia; Hepatectomia; Neoplasias Hepáticas/terapia; Recidiva Local de Neoplasia/tratamento farmacológico; Niacinamida/análogos & derivados; Compostos de Fenilureia/uso terapêutico; Adolescente; Adulto; Idoso; Carcinoma Hepatocelular/tratamento farmacológico; Carcinoma Hepatocelular/patologia; Carcinoma Hepatocelular/cirurgia; Quimioterapia Adjuvante; Terapia Combinada; Intervalo Livre de Doença; Feminino; Humanos; Neoplasias Hepáticas/tratamento farmacológico; Neoplasias Hepáticas/patologia; Neoplasias Hepáticas/cirurgia; Masculino; Pessoa de Meia-Idade; Estadiamento de Neoplasias; Niacinamida/efeitos adversos; Niacinamida/uso terapêutico; Compostos de Fenilureia/efeitos adversos; Estudos Prospectivos; Estudos Retrospectivos; Fatores de Risco; Sorafenibe; Espanha; Taxa de Sobrevida; Resultado do Tratamento; Adulto Jovem

Palavras-chave

Hepatectomy; Hepatocellular carcinoma; Sorafenib; Survival; Tumor recurrence

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google